{"id":"dabigatran-ticagrelor","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Gastrointestinal bleeding"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dabigatran directly inhibits thrombin (Factor IIa), blocking the final step of the coagulation cascade and preventing clot formation. Ticagrelor irreversibly blocks the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. Together, they provide complementary anticoagulant and antiplatelet mechanisms for enhanced thrombotic protection in acute coronary syndromes or high-risk cardiovascular conditions.","oneSentence":"This combination uses dabigatran (a direct thrombin inhibitor) and ticagrelor (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:03.586Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with dual anticoagulant-antiplatelet therapy"}]},"trialDetails":[{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT03234114","phase":"PHASE4","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-03","conditions":"Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)","enrollment":3746},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT04688723","phase":"PHASE4","title":"Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI","status":"UNKNOWN","sponsor":"Zuyderland Medisch Centrum","startDate":"2020-12-23","conditions":"Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction","enrollment":1000},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT02164864","phase":"PHASE3","title":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-22","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2725},{"nctId":"NCT01734772","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-11","conditions":"Healthy","enrollment":48},{"nctId":"NCT01812200","phase":"PHASE4","title":"Antithrombotic Triple Therapy in Humans","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-10","conditions":"Atrial Fibrillation, Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT01595854","phase":"PHASE1","title":"Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-05","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dabigatran + Ticagrelor","genericName":"Dabigatran + Ticagrelor","companyName":"Zuyderland Medisch Centrum","companyId":"zuyderland-medisch-centrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dabigatran and Ticagrelor are used in combination to treat conditions such as atrial fibrillation and acute ischemic stroke, as well as in patients who have undergone percutaneous coronary intervention. Ticagrelor works as a small molecule negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}